KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based treatment. Methods: Advanced NSCLC patients tested for KRAS mutation (n = 334) were retrospectively reviewed and 252 patients with wild type epidermal growth factor receptor and no anaplastic lymphoma kinase fusion were enrolled for the analysis. KRAS mutations were observed in 45 subjects with mutation type as followed: G12C (n = 13), G12D (n = 12), G12V (n = 12), other (n = 8). Response rate (RR), progression- free survival (PFS), and overall survival (OS) of pemetrexed singlet and gemcitabine based chemotherapy were analysis. Results: Age, sex, performance status were well balanced between subjects with or without KRAS mutations. No difference was observed in RR. Hazard ratio (HR) of PFS for pemetrexed treated subjects with G12C mutation compared to subjects with KRAS wild type was 1.96 (95% confidential interval [CI], 1.01 to 3.79; p = 0.045), but other mutations failed to show clinical significance. By analysis done by PFS, compared to the subjects with transition mutation, HR was 1.48 (95% CI, 0.64 to 3.40; p = 0.360) for subjects with transversion mutation on pemetrexed treatment and 0.41 (95% CI, 0.19 to 0.87; p = 0.020) for subjects treated with gemcitabine based chemotherapy. No difference was observed in OS. Conclusions: In this study, different drug sensitivity was observed according to the type of KRAS mutation. NSCLC subpopulations with different KRAS mutation type should be considered as different subgroups and optimal chemotherapy regimens should be searched in further confirmative studies.
Abstract
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based treatment. Methods: Advanced NSCLC patients tested for KRAS mutation (n = 334) were retrospectively reviewed and 252 patients with wild type epidermal growth factor receptor and no anaplastic lymphoma kinase fusion were enrolled for the analysis. KRAS mutations were observed in 45 subjects with mutation type as followed: G12C (n = 13), G12D (n = 12), G12V (n = 12), other (n = 8). Response rate (RR), progression- free survival (PFS), and overall survival (OS) of pemetrexed singlet and gemcitabine based chemotherapy were analysis. Results: Age, sex, performance status were well balanced between subjects with or without KRAS mutations. No difference was observed in RR. Hazard ratio (HR) of PFS for pemetrexed treated subjects with G12C mutation compared to subjects with KRAS wild type was 1.96 (95% confidential interval [CI], 1.01 to 3.79; p = 0.045), but other mutations failed to show clinical significance. By analysis done by PFS, compared to the subjects with transition mutation, HR was 1.48 (95% CI, 0.64 to 3.40; p = 0.360) for subjects with transversion mutation on pemetrexed treatment and 0.41 (95% CI, 0.19 to 0.87; p = 0.020) for subjects treated with gemcitabine based chemotherapy. No difference was observed in OS. Conclusions: In this study, different drug sensitivity was observed according to the type of KRAS mutation. NSCLC subpopulations with different KRAS mutation type should be considered as different subgroups and optimal chemotherapy regimens should be searched in further confirmative studies.
참고문헌 (33)
- Molina JR, "Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship", Mayo Clin Proc, 83, pp.584~594 (2008)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
- Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)
- Suda K, "Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation", Cancer Metastasis Rev, 29, pp.49~60 (2010)
- Shankaran V, "Predicting response to EGFR inhibitors in metastatic colorectal cancer:current practice and future directions", Oncologist, 15, pp.157~167 (2010)
- Kris MG, "Identification of driver mutations in tumor specimens from 1,000patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC)", J Clin Oncol, 29, pp.CRA7506~ (2011)
- Graziano SL, "Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer", J Clin Oncol, 17, pp.668~675 (1999)
- Mao C, "KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies", Lung Cancer, 69, pp.272~278 (2010)
- Riely GJ, "Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma", Clin Cancer Res, 14, pp.5731~5734 (2008)
- Schubbert S, "Hyperactive Ras in developmental disorders and cancer", Nat Rev Cancer, 7, pp.295~308 (2007)
- Mascaux C, "The role of RAS oncogene in survival of patients with lung cancer: a sys-tematic review of the literature with meta-analysis", Br J Cancer, 92, pp.131~139 (2005)
- Cadranel J, "Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project: part 2)", J Thorac Oncol, 7, pp.1490~1502 (2012)
- Meng D, "Prognostic value of K-RAS mutations in patients with non-small cell lung cancer:a systematic review with meta-analysis", Lung Cancer, 81, pp.1~10 (2013)
- Zalcman G, "Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer", J Clin Oncol, 26(15 Suppl), pp.7500~ (2008)
- D’Angelo SP, "Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib", J Thorac Oncol, 7, pp.1815~1822 (2012)
- Loriot Y, "Are RAS mutations predictive markers of resistance to standard chemotherapy?", Nat Rev Clin Oncol, 6, pp.528~534 (2009)
- Moran DM, "KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells", Mol Cancer Ther, 13, pp.1611~1624 (2014)
- Sun JM, "Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer", PLoS One, 8, pp.e64816~ (2013)
- Rodenhuis S, "Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study", J Clin Oncol, 15, pp.285~291 (1997)
- Janne PA, "Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC)", J Clin Oncol, 30, pp.7503~ (2012)
- Sequist LV, "Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer", J Clin Oncol, 29, pp.3307~3315 (2011)
- Roberts PJ, "KRAS mutation: should we test for it, and does it matter?", J Clin Oncol, 31, pp.1112~1121 (2013)
- Lee YJ, "Lung cancer in never smokers: change of a mindset in the molecular era", Lung Cancer, 72, pp.9~15 (2011)
- Dogan S, "Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas:higher susceptibility of women to smoking-related KRAS-mutant cancers", Clin Cancer Res, 18, pp.6169~6177 (2012)
- Andreyev HJ, "Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study", Br J Cancer, 85, pp.692~696 (2001)
- Kim ES, "The BATTLE trial:personalizing therapy for lung cancer", Cancer Discov, 1, pp.44~53 (2011)
- Ihle NT, "Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome", J Natl Cancer Inst, 104, pp.228~239 (2012)
- Garassino MC, "Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer", Ann Oncol, 22, pp.235~237 (2011)
- mutation, "J Thorac Oncol", 2012, 833~840
- Macerelli M, "Does KRAS mutational status predict chemoresistance in advanced nonsmall cell lung cancer (NSCLC)?", Lung Cancer, 83, pp.383~388 (2014)
- Kamdar MK, "KRAS gene mutation status and sensitivity to pemetrexed: a retrospective analysis", J Clin Oncol, 31, pp.e19154~ (2013)
- Reck M, "Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 25(Suppl 3), pp.iii27~iii39 (2014)